SS
SAGE

Simplicity Solutions’s Sage Therapeutics SAGE Stock Holding History

Simplicity Solutions’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,465
Closed -$206K – 866
2019
Q3 		$206K Buy
1,465
+1
+0.1% +$167 0.01% 677
2019
Q2 		$268K Buy
1,464
+1
+0.1% +$171 0.01% 533
2019
Q1 		$233K Buy
+1,463
New +$212K 0.01% 630
2016
Q1 		– Sell
-7,810
Closed -$455K – 448
2015
Q4 		$455K Buy
+7,810
New +$387K 0.05% 468

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Simplicity Solutions's SAGE Position: Q4 2019 in Review

Simplicity Solutions sold out of Sage Therapeutics (SAGE) in Q4 2019, closing a stake of 1,465 shares — an estimated $206K sold.

Simplicity Solutions first reported a position in SAGE in Q4 2015 and held it in 4 quarters. The position peaked at $455K in Q4 2015. 266 funds tracked by Wall St. Rank hold SAGE as of Q4 2019.

  • Simplicity Solutions reported no remaining Sage Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Simplicity Solutions sold 1,465 Sage Therapeutics shares in Q4 2019, an estimated $206K.
  • Simplicity Solutions first reported a position in Sage Therapeutics in Q4 2015 and held it in 4 quarters.
  • Simplicity Solutions's Sage Therapeutics position peaked at $455K in Q4 2015.
  • 266 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2019.

Based on Simplicity Solutions's 13F filing for Q4 2019, filed 12 Feb 2020.